Form 4 for CAMP Camp4 Therapeutics Corp
Accepted 2025-09-15 00:00:00 ET · period of report 2025-09-11 · accession 0001231919-25-000196 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-09-15 | 2025-09-11 | CAMP | 5AM Ventures VII, L.P. | 10% | P - Purchase | $1.53 | +2.94M | 2.94M | New | +$4.50M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-11 | P | A | 2,941,176 | $1.53 | 2,941,176 | I By 5AM Ventures VII, L.P. | — | — | (F1) The shares are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. |